The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Open accessAbstract
BACKGROUND: Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration-approved medical therapy is available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease. METHODS: In a randomized, double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid eye disease in a 1:1 ratio to receive intravenous infusions of the IGF-IR inhibitor teprotumumab (10 mg per kilogram of body weight for the first infusion and 20 mg per kilogram for subsequent infusions) or placebo once every 3 weeks for 21 weeks; the last trial visit for this analysis was at week 24. The primary outcome was a proptosis response (a reduction in proptosis of ≥2 mm) at week 24. Prespecified secondary outcomes at week 24 were an overall response (a reduction of ≥2 points in the Clinical Activity Score plus a reduction in proptosis of ≥2 mm), a Clinical Activity Score of 0 or 1 (indicating no or minimal inflammation), the mean change in proptosis across trial visits (from baseline through week 24), a diplopia response (a reduction in diplopia of ≥1 grade), and the mean change in overall score on the Graves' ophthalmopathy-specific quality-of-life (GO-QOL) questionnaire across trial visits (from baseline through week 24; a mean change of ≥6 points is considered clinically meaningful). RESULTS: A total of 41 patients were assigned to the teprotumumab group and 42 to the placebo group. At week 24, the percentage of patients with a proptosis response was higher with teprotumumab than with placebo (83% [34 patients] vs. 10% [4 patients], P<0.001), with a number needed to treat of 1.36. All secondary outcomes were significantly better with teprotumumab than with placebo, including overall response (78% of patients [32] vs. 7% [3]), Clinical Activity Score of 0 or 1 (59% [24] vs. 21% [9]), the mean change in proptosis (-2.82 mm vs. -0.54 mm), diplopia response (68% [19 of 28] vs. 29% [8 of 28]), and the mean change in GO-QOL overall score (13.79 points vs. 4.43 points) (P≤0.001 for all). Reductions in extraocular muscle, orbital fat volume, or both were observed in 6 patients in the teprotumumab group who underwent orbital imaging. Most adverse events were mild or moderate in severity; two serious events occurred in the teprotumumab group, of which one (an infusion reaction) led to treatment discontinuation. CONCLUSIONS: Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon. (Funded by Horizon Therapeutics; OPTIC ClinicalTrials.gov number, NCT03298867, and EudraCT number, 2017-002763-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Self-citationClinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Teprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Self-citationSmoking and Risk of Graves' Disease
Prummel, M. F. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040045034 · Cited by 503
Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3014 · Cited by 412
Self-citationIntravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Zang, S., Ponto, K. A., & Kahaly, G. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1962 · Cited by 379
Self-citationTsui, S., Naik, V., Hoa, N., Hwang, C. J., Afifiyan, N. F., Sinha Hikim, A., Gianoukakis, A. G., Douglas, R. S., & Smith, T. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4397 · Cited by 372
Self-citationBartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Self-citationRandomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2572 · Cited by 369
Bartley, G. B. (1994) · PubMed · Cited by 363
Adipogenesis: forces that tip the scales
MacDougald, O. A., & Mandrup, S. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00517-3 · Cited by 355
Terwee, C. B., Gerding, M. N., Dekker, F. W., Prummel, M. F., & Wiersinga, W. M. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.7.773 · Cited by 321
_, _., Wiersinga, W. M., Perros, P., Kahaly, G. J., Mourits, M. P., Baldeschi, L., Boboridis, K., Boschi, A., Dickinson, A. J., Kendall-Taylor, P., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02230 · Cited by 302
Self-citationPerez-Moreiras, J. V., Gomez-Reino, J. J., Maneiro, J. R., Perez-Pampin, E., Romo Lopez, A., Rodríguez Alvarez, F. M., Castillo Laguarta, J. M., del Estad Cabello, A., Gessa Sorroche, M., España Gregori, E., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.038 · Cited by 300
Pritchard, J., Han, R., Horst, N., Cruikshank, W. W., & Smith, T. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6348 · Cited by 295
Self-citationRUNDLE, F. F., & Wilson, C. W. (1945) · PubMed · Cited by 259
Smith, T. J., & Hoa, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0716 · Cited by 256
Self-citationGlucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖)
Perez, A., Jansen‐Chaparro, S., Saigi, I., Bernal‐Lopez, M. R., Miñambres, I., & Gomez‐Huelgas, R. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12090 · Cited by 240
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy
Smith, T. J., & Janssen, J. A. M. J. L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00066 · Cited by 231
Self-citationPrummel, M., Bakker, A., Wiersinga, W., Baldeschi, L., Mourits, M., Kendall-Taylor, P., Perros, P., Neoh, C., Dickinson, A., Lazarus, J., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480491 · Cited by 213
Self-citationTerwee, C. B., Dekker, F. W., Mourits, M. P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., & Wiersinga, W. M. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01241.x · Cited by 202
Douglas, R. S., Gianoukakis, A. G., Kamat, S., & Smith, T. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3281 · Cited by 157
Self-citationDouglas, R. S., Naik, V., Hwang, C. J., Afifiyan, N. F., Gianoukakis, A. G., Sand, D., Kamat, S., & Smith, T. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5768 · Cited by 148
Self-citationvan Geest, R. J., Sasim, I. V., Koppeschaar, H. P. F., Kalmann, R., Stravers, S., Bijlsma, W. R., & Mourits, M. P. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0558 · Cited by 127
Quality of Life in a German Graves Orbitopathy Population
Ponto, K. A., Hommel, G., Pitz, S., Elflein, H. M., Pfeiffer, N., & Kahaly, G. J. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.02.018 · Cited by 115
Self-citationQuality of Life and Occupational Disability in Endocrine Orbitopathy
Ponto, K. A., Pitz, S., Pfeiffer, N., Hommel, G., Weber, M. M., & Kahaly, G. J. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0283 · Cited by 65
Self-citationReliability of Estimating Ductions in Thyroid Eye Disease
Dolman, P. J., Cahill, K. V., Czyz, C. N., Douglas, R. S., Elner, V. M., Feldon, S. E., Kazim, M., Lucarelli, M. J., Sivak-Callcott, J. A., Stacey, A. W., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.07.011 · Cited by 62
Self-citationArrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk
Krieger, C. C., Boutin, A., Jang, D., Morgan, S. J., Banga, J. P., Kahaly, G. J., Kłubo-Gwieździńska, J., Neumann, S., & Gershengorn, M. C. (2019) · Endocrinology · doi:10.1210/en.2019-00055 · Cited by 55
Self-citationNovel aspects of orbital fibroblast pathology
Smith, T. J. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345273 · Cited by 40
Self-citationManagement of Moderately Severe Graves’Orbitopathy
Kahaly, G. J. (2007) · KARGER eBooks · doi:10.1159/000107455 · Cited by 17
Self-citation
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationEpidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
Bartalena, L., Piantanida, E., Gallo, D., Lai, A., & Tanda, M. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.615993 · Cited by 369
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Kaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
Wang, Y., Chen, Z., Wang, T., Guo, H., Liu, Y., Dang, N., Hu, S., Wu, L., Zhang, C., Ye, K., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00615-2 · Cited by 82
Metadata
- Authors
- Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., Antonelli, A., Dailey, R., Harris, G. J., Eckstein, A., Schiffman, J., Tang, R., Nelson, C., Salvi, M., Wester, S., Sherman, J. W., Vescio, T., Holt, R. J., & Smith, T. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-23
- Volume
- 382
- Issue
- 4
- Pages
- 341-352
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3001519864
- Cited by
- 752
- References
- 30
- FWCI
- 54.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.